

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC COLLABORATION WITH
MEDBANKS HEALTH TECHNOLOGY CO., LTD
TO DEVELOP INNOVATIVE HEALTHCARE SERVICE
SOLUTIONS FOR PATIENTS IN CHINA**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis, to provide latest business update to the shareholders and potential investors of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has entered into a strategic collaboration with Medbanks Health Technology Co., Ltd (“**Medbanks**”), a pharmacy and healthcare services provider specializing in oncology.

The Company and Medbanks’ strategic collaboration will focus on leveraging the specialized nationwide direct-to-patient pharmacy network of Medbanks to develop innovative healthcare service solutions for oncology and special care, including a new service model to address the unmet needs of patients in these expansive disease areas. This collaboration positions the Company to enable more patients to have access to its novel medicines.

In addition, the Company and Medbanks will collaborate on patient education, explore opportunities to gather real-world data using Medbanks’s database and out-patient system, and work to establish a model to improve disease management for oncology and other severe diseases through Medbanks’s online platform and dedicated patient service team.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, July 13, 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.